Phase 2/3 Trial of Oral Troriluzole in Easing Alzheimer’s Dementia Fully Enrolled

Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow…

Biohaven Enrolls 1st Patient in Phase 2/3 Trial of Trigriluzole for Mild to Moderate Alzheimer’s

Biohaven Pharmaceuticals has enrolled the first patient in its Phase 2/3 clinical trial investigating the potential of trigriluzole as a treatment for patients with mild to moderate Alzheimer’s disease. The study, which is currently recruiting, is being conducted in collaboration with the Alzheimer’s Disease Cooperative Study (ADCS)…